for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Neximmune Inc

NEXI.OQ

Latest Trade

16.36USD

Change

-0.13(-0.79%)

Volume

13,438

Today's Range

16.00

 - 

16.49

52 Week Range

10.11

 - 

27.80

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
16.49
Open
16.30
Volume
13,438
3M AVG Volume
1.70
Today's High
16.49
Today's Low
16.00
52 Week High
27.80
52 Week Low
10.11
Shares Out (MIL)
22.63
Market Cap (MIL)
374.04
Forward P/E
-6.29
Dividend (Yield %)
--

Latest Developments

More

Neximmune Posts Q1 Loss Per Share Of $0.71

Neximmune Reports Fiscal Year 2020 Financial Results And Recent Updates

Neximmune Says Anticipate IPO Price Will Be Between $15 And $17 Per Share

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Neximmune Inc

NexImmune, Inc is a clinical-stage biotechnology company. The Company is engaged in developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. The Company provides Artificial Immune Modulation (AIM) which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. Its T cell product candidates are designed to combine the attributes of cellular with reduced potential for toxicities. The Company’s two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation and multiple myeloma refractory to lines of therapy, respectively.

Industry

Business Services

Contact Info

9119 GAITHER ROAD

GAITHERSBURG, MD

20878

United States

+1.301.8259810

https://www.neximmune.com/

Executive Leadership

Sol J. Barer

Independent Chairman of the Board

Scott Carmer

President, Chief Executive Officer, Director

John Trainer

Chief Financial Officer

Kristi Jones

Chief Operating Officer

Jerome Zeldis

Executive Vice President - Research and Development

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2021(E)

0.0K
EPS (USD)

2021(E)

-2.623
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.40
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up